Drug Patents owned by Global Blood Theraps
1. Drug name - OXBRYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10034879 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(10 years from now) | |
| US9018210 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(10 years from now) | |
| US10806733 | GLOBAL BLOOD THERAPS | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
Dec, 2032
(10 years from now) | |
| US9447071 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(12 years from now) | |
| CN105431147A | GLOBAL BLOOD THERAPS | 2-Hydroxy--6-((2-(1-Isopropyl--1H-Pyrazol--5-Yl) Pyridine--3-Yl) Methoxy) Benzaldehyde And Free Alkali Is Crystalline Polymorph |
Apr, 2022
(5 months ago) | |
| CN107176953A | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| CN104135859A | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| CN104135859B | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compound And Its Method For Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| CN107176953B | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compound And Method For Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| IN322527B | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| EP3141542B1 | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| EP3141542A1 | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| EP2797416A4 | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| EP2797416A1 | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| EP2797416B1 | GLOBAL BLOOD THERAPS | Substituted Benzaldehyde Compounds And Methods For Their Use In Increasing Tissue Oxygenation |
Dec, 2032
(10 years from now) | |
| EP3102208A1 | GLOBAL BLOOD THERAPS | Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde |
Feb, 2035
(12 years from now) | |
| EP3102208A4 | GLOBAL BLOOD THERAPS | Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde |
Feb, 2035
(12 years from now) | |
| EP3102208B1 | GLOBAL BLOOD THERAPS | Crystalline Polymorph Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde |
Feb, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10017491 | GLOBAL BLOOD THERAPS | Compounds and uses thereof for the modulation of hemoglobin |
Dec, 2032
(10 years from now) | |
| US9248199 | GLOBAL BLOOD THERAPS | 1:1 adducts of sickle hemoglobin |
Jan, 2034
(11 years from now) | |
| US10722502 | GLOBAL BLOOD THERAPS | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Feb, 2035
(12 years from now) | |
| US11020382 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(14 years from now) | |
| US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(15 years from now) | |
Drugs and Companies using VOXELOTOR ingredient
Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; treatment of sickle cell disease by administering voxelotor, as recited in claim 2; Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 500MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.